| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 12 Aug 2026 | 5 Aug 2026 |
| Quarterly Results Board of directors of the Company met on Wednesday, August 12 2026 inter alia transacted the following business. 1. Considered and approved the unaudited Financial Results (Standalone and Consolidated) of the Company quarter ended on 30th June, 2026 2. Approved the change in designation of Mr. Ravindra Kumar Kothari (DIN: 03418320) from Non-Executive Director to Whole-Time Director, 3. Approved the change in designation of Mr. Virupakshaya Himesh (DIN: 08554422) from Whole-Time Director to Non-Executive Director, with effect from October 1, 2026 4. Approved the proposal to make investment in the proposed Joint Venture entity to be incorporated in the Republic of the Philippines 5 approved the allotment of 10,00,000 (Ten Lakhs) Warrants to Mr. Shailesh Siroya, Promoter of the Company, on preferential basis (As per BSE Announcement dated on: 12.08.2026) | ||
| Board Meeting | 27 May 2026 | 18 May 2026 |
| Employees Stock Option Plan & Audited Results & Final Dividend Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve 1. Audited financial results of the Company for the quarter and financial year ended 31.03.2026. 2. Audited standalone and consolidated accounts of the Company together with auditors report, for the F.Y ended 31.03.2026. 3. To recommend dividend if any, for the F.Y 2025.26. 4. To grant stock options to the employees of the Company under Bal Pharma Ltd- Employee Stock Option Plan 2025 Board of Directors of the Company has met today and transacted following business, 1. Approved audited financial results of the Company for the quarter and financial year ended 31.03.2026. 2.Recommend dividend of Rs1.20 per equity share of Rs.10 each i.e 12% 3.Appointed Cost Auditors and Internal auditors for the financial year 2026.27. 4. Approved grant of 5,00,000 stock options to the employees of the company under Bal Pharma Ltd-Employee Stock Option Plan-2025 5.Approved preferential issue of 10,00,000 warrants to the promoters. 6. Take shareholders approval for preferential issue through postal ballot. 7.Approved appointment of Mr.Shreepada M.L (M # A66681) as Company Secretary and compliance officer of the company. (As Per BSE Announcement Dated on:27.05.2026) This is with reference to our earlier intimation dated 27th May 2026 regarding appointment of Mr. Shreepada ML as company secretary and compliance officer of the company pursuant to the approval of the board of directors at its meeting held on 27th may 2026 , we hereby confirm that Mr. Shreepada ML (M No A66681) has taken charge and commenced his duties as the company Secretary and compliance officer (KMP) of the Company with effect from 23rd June 2026. (As Per BSE Announcement Dated on 24.06.2026) | ||
| Board Meeting | 11 Feb 2026 | 3 Feb 2026 |
| Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 inter alia to consider and approve Unaudited standalone and consolidated financial results of the Company for the quarter ended 31.12.2025. Unaudited standalone and consolidated financial results for the quarter ended 31.12.2025. (As Per BSE Announcement Dated on 11.02.2026) | ||
| Board Meeting | 12 Nov 2025 | 4 Nov 2025 |
| Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 inter alia to consider and approve standalone and consolidated financial results of the Company for the quarter and half year ended 30.09.2025. Board of Directors of the Company has inter alia 1. Approved the unaudited standalone and consolidate financial results for the quarter ended 30.09.2025. 2. Appointed Dr.B.Mukesh ( DIN # 11295580)as additional Director of the Company. (As Per BSE Announcement Dated on 12.11.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
